Shareholding disclosure

UBS Group AG

Declared position

7.97%

Threshold

Crossed upwards

Timeline

Published

08.05.2024

Transaction

29.04.2024

Voting rights breakdown

Voting rights acquired7.97%

Voting rights sold0.876%

Below threshold0%

Notice details

CategorySingle shareholder

ExchangeXSWX

Notification ID

ZA01-000000000OH46

Beneficial owner

UBS Group AG

Declared address

UBS Group AG, Zurich, CH

Open shareholder profile Open company profile

Back to the feed

Shareholding disclosure

UBS Group AG

Basilea Pharmaceutica AG, Allschwil08.05.2024ZA01-000000000OH46

Disclosure summary

UBS Group AG disclosed a holding in Basilea Pharmaceutica AG, Allschwil on the acquisition side, published by SIX Exchange Regulation on 08.05.2024, at 7.97% of voting rights. Notice category: Single shareholder.

Disclosed position

7.97%

Voting rights acquired

Voting rights acquired7.97%

Voting rights sold0.876%

Below threshold0%

Never miss a market signal again

Create a free account

Need more? Discover the Pro plan

Pro alertsEmail and Telegram after publication

Unlimited company trackingUnlimited watchlist with the Pro plan

Monday recapYour stocks' essentials at the open

Disclosure detail

UBS Group AG disclosed a holding in Basilea Pharmaceutica AG, Allschwil, published on 08.05.2024.

Publication date08.05.2024

Transaction date29.04.2024

Issuing companyBasilea Pharmaceutica AG, Allschwil

Beneficial ownerUBS Group AG

Declared addressUBS Group AG, Zurich, CH

CategorySingle shareholder

Voting rights acquired7.97%

Voting rights sold0.876%

Below threshold0%

ExchangeXSWX

Notification IDZA01-000000000OH46

Commercial register

CHE-395.345.924

Registered

Zefix record

Source: SIX Exchange Regulation · Publication date: 08.05.2024

These figures aggregate public disclosures. They are not investment advice.

insider24.ch

Never miss a market signal again

Create a free account

Need more? Discover the Pro plan

Pro alertsEmail and Telegram after publication

Unlimited company trackingUnlimited watchlist with the Pro plan

Monday recapYour stocks' essentials at the open